Melanoma pathophysiology and drug targets

Giuseppe Palmieri, Carla Rozzo, Giusy Gentilcore, Paolo Antonio Ascierto

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

In fair-skinned populations, both incidence and mortality rates of melanoma have been increasing over the past decades. Melanoma incidence has been found to vary according to the population's origin, with the highest rates in Australia, the USA and North Europe. A combination of an intermittent exposure to UV radiation with endogenous factors, such as a light phototype, higher number of nevi and family history for melanoma increases the risk of the disease. Although several genetic and molecular alterations have been identified, pathogenesis of melanoma is mostly due to a sequence of interactions between key effectors in three molecular pathways: CDKN2A (with a role in both susceptibility and tumorigenesis), MAPK and PI3K/AKT. Demonstration that a complex molecular scenario underlies development and progression of the disease confirms the existence of several distinct subtypes of melanoma and, therefore, distinct subsets of patients with putative differences in tumor behavior (which may determine a wide range of variations in prognosis and response to therapy).

Original languageEnglish
Title of host publicationEmerging Therapeutics for Melanoma
PublisherFuture Medicine Ltd.
Pages7-17
Number of pages11
ISBN (Electronic)9781780840321
ISBN (Print)9781780841168
DOIs
Publication statusPublished - 1 Jan 2012
Externally publishedYes

Fingerprint

Melanoma
Pharmaceutical Preparations
Nevus
Incidence
Phosphatidylinositol 3-Kinases
Population
Disease Progression
Molecular Biology
Carcinogenesis
Radiation
Light
Mortality
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Palmieri, G., Rozzo, C., Gentilcore, G., & Ascierto, P. A. (2012). Melanoma pathophysiology and drug targets. In Emerging Therapeutics for Melanoma (pp. 7-17). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.29

Melanoma pathophysiology and drug targets. / Palmieri, Giuseppe; Rozzo, Carla; Gentilcore, Giusy; Ascierto, Paolo Antonio.

Emerging Therapeutics for Melanoma. Future Medicine Ltd., 2012. p. 7-17.

Research output: Chapter in Book/Report/Conference proceedingChapter

Palmieri, G, Rozzo, C, Gentilcore, G & Ascierto, PA 2012, Melanoma pathophysiology and drug targets. in Emerging Therapeutics for Melanoma. Future Medicine Ltd., pp. 7-17. https://doi.org/10.2217/EBO.11.29
Palmieri G, Rozzo C, Gentilcore G, Ascierto PA. Melanoma pathophysiology and drug targets. In Emerging Therapeutics for Melanoma. Future Medicine Ltd. 2012. p. 7-17 https://doi.org/10.2217/EBO.11.29
Palmieri, Giuseppe ; Rozzo, Carla ; Gentilcore, Giusy ; Ascierto, Paolo Antonio. / Melanoma pathophysiology and drug targets. Emerging Therapeutics for Melanoma. Future Medicine Ltd., 2012. pp. 7-17
@inbook{0bdbba457a3142efa310dc5a5656f4a3,
title = "Melanoma pathophysiology and drug targets",
abstract = "In fair-skinned populations, both incidence and mortality rates of melanoma have been increasing over the past decades. Melanoma incidence has been found to vary according to the population's origin, with the highest rates in Australia, the USA and North Europe. A combination of an intermittent exposure to UV radiation with endogenous factors, such as a light phototype, higher number of nevi and family history for melanoma increases the risk of the disease. Although several genetic and molecular alterations have been identified, pathogenesis of melanoma is mostly due to a sequence of interactions between key effectors in three molecular pathways: CDKN2A (with a role in both susceptibility and tumorigenesis), MAPK and PI3K/AKT. Demonstration that a complex molecular scenario underlies development and progression of the disease confirms the existence of several distinct subtypes of melanoma and, therefore, distinct subsets of patients with putative differences in tumor behavior (which may determine a wide range of variations in prognosis and response to therapy).",
author = "Giuseppe Palmieri and Carla Rozzo and Giusy Gentilcore and Ascierto, {Paolo Antonio}",
year = "2012",
month = "1",
day = "1",
doi = "10.2217/EBO.11.29",
language = "English",
isbn = "9781780841168",
pages = "7--17",
booktitle = "Emerging Therapeutics for Melanoma",
publisher = "Future Medicine Ltd.",
address = "United Kingdom",

}

TY - CHAP

T1 - Melanoma pathophysiology and drug targets

AU - Palmieri, Giuseppe

AU - Rozzo, Carla

AU - Gentilcore, Giusy

AU - Ascierto, Paolo Antonio

PY - 2012/1/1

Y1 - 2012/1/1

N2 - In fair-skinned populations, both incidence and mortality rates of melanoma have been increasing over the past decades. Melanoma incidence has been found to vary according to the population's origin, with the highest rates in Australia, the USA and North Europe. A combination of an intermittent exposure to UV radiation with endogenous factors, such as a light phototype, higher number of nevi and family history for melanoma increases the risk of the disease. Although several genetic and molecular alterations have been identified, pathogenesis of melanoma is mostly due to a sequence of interactions between key effectors in three molecular pathways: CDKN2A (with a role in both susceptibility and tumorigenesis), MAPK and PI3K/AKT. Demonstration that a complex molecular scenario underlies development and progression of the disease confirms the existence of several distinct subtypes of melanoma and, therefore, distinct subsets of patients with putative differences in tumor behavior (which may determine a wide range of variations in prognosis and response to therapy).

AB - In fair-skinned populations, both incidence and mortality rates of melanoma have been increasing over the past decades. Melanoma incidence has been found to vary according to the population's origin, with the highest rates in Australia, the USA and North Europe. A combination of an intermittent exposure to UV radiation with endogenous factors, such as a light phototype, higher number of nevi and family history for melanoma increases the risk of the disease. Although several genetic and molecular alterations have been identified, pathogenesis of melanoma is mostly due to a sequence of interactions between key effectors in three molecular pathways: CDKN2A (with a role in both susceptibility and tumorigenesis), MAPK and PI3K/AKT. Demonstration that a complex molecular scenario underlies development and progression of the disease confirms the existence of several distinct subtypes of melanoma and, therefore, distinct subsets of patients with putative differences in tumor behavior (which may determine a wide range of variations in prognosis and response to therapy).

UR - http://www.scopus.com/inward/record.url?scp=84882442590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882442590&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.29

DO - 10.2217/EBO.11.29

M3 - Chapter

AN - SCOPUS:84882442590

SN - 9781780841168

SP - 7

EP - 17

BT - Emerging Therapeutics for Melanoma

PB - Future Medicine Ltd.

ER -